Eidos Therapeutics, Inc. Common Stock
EIDX
EIDX was delisted on the 25th of January, 2021.
45 hedge funds and large institutions have $174M invested in Eidos Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$45.3M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$41.6M |
| 3 |
PA
Perceptive Advisors
New York
|
+$14.4M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.09M |
| 5 |
DM
Deerfield Management
New York
|
+$6.79M |
Top Sellers
EIDX Hedge Fund Activity: Q2 2018 in Review
45 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q2 2018, worth a combined $174M.
Buyers outnumbered sellers: 45 funds opened new EIDX positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $45.3M.
- 45 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $174M of Eidos Therapeutics, Inc. Common Stock stock for Q2 2018.
- 45 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q2 2018 and 0 closed out, a net change of +45 holders.
- The largest Eidos Therapeutics, Inc. Common Stock buyer in Q2 2018 was RA Capital Management, an estimated $45.3M added.
Based on aggregated 13F filings for Q2 2018.